S&S Lab and MYSC have partnered to integrate Korea’s largest private shared laboratory infrastructure with a 100 billion KRW impact investment fund. This alliance creates an end-to-end growth platform for bio deep tech startups, solving the critical capex bottleneck. For founders, this means unprecedented access to lab space, capital, and cross-border PoC opportunities in Southeast Asia.
The Deep Tech Capex Dilemma
For founders in bio deep tech, healthcare, and precision materials, the barrier to entry is notoriously high due to massive upfront capital expenditure (CAPEX) requirements. Building a functional laboratory and acquiring specialized equipment can consume millions of dollars before a single experiment is conducted. Historically in Korea, startups have relied on public bio-clusters like Osong and Songdo. However, these public facilities often face criticism for their rigid operational structures, slow administrative processes, and a lack of direct linkage to commercialization and venture capital networks. As the global deep tech bio sector booms—projected to grow from $1.55 trillion in 2023 to $4.22 trillion by 2033—agile, private-sector solutions are becoming essential for startups needing to iterate quickly.
The “LabCentral” of Asia: Infrastructure Meets Capital
The recently announced MOU between S&S Lab and MYSC represents a paradigm shift in the Korean ecosystem, mirroring the successful models of US-based LabCentral and BioLabs. S&S Lab operates the largest private shared lab space in Korea, boasting 850 pyeong (approximately 30,000 sq ft) across key Seoul tech hubs like Seongsu and Guro. By joining forces with MYSC, an impact investment firm managing 100 billion KRW (approx. $72 million USD), the partnership transcends mere real estate. It creates a comprehensive growth platform that bundles state-of-the-art R&D infrastructure with targeted open innovation programs and a dedicated global fund. This means founders can simultaneously secure the physical space needed for R&D and the capital required to scale, all within a single ecosystem.
Bridging Korea and Southeast Asia
A critical differentiator of this alliance is its strategic focus on global expansion, specifically targeting Southeast Asia. S&S Lab has proactively established hubs in Bangkok, Thailand, and Jakarta, Indonesia. When combined with MYSC’s global funding initiatives, this infrastructure provides Korean bio startups with a fast-track mechanism for cross-border Proof of Concept (PoC). Southeast Asia offers a rapidly growing market with diverse clinical needs and, in some cases, more agile regulatory pathways for initial testing. Startups can conduct core R&D in Seoul and rapidly execute pilot programs or regulatory checks in Southeast Asia, potentially reducing time-to-market by 6 to 12 months compared to building independent overseas operations.
Strategic Implications and Actionable Takeaways for Founders
For bio deep tech founders, this integrated model offers a strategic advantage that must be leveraged early in the company’s lifecycle.
1. Convert CAPEX to OPEX: Do not raise venture capital to buy basic lab equipment or build out facilities. Utilize shared platforms like S&S Lab to turn fixed costs into manageable operational expenses. Redirect your seed funding entirely toward talent acquisition, core IP development, and generating robust PoC data.
2. Leverage the Internal Ecosystem for Funding: Treat your physical presence in these shared labs as an ongoing pitch. Actively participate in the joint open innovation programs hosted by MYSC and S&S Lab. Align your milestones with their global fund mandates to streamline your path to Seed extension or Series A funding.
3. Build a Southeast Asia Strategy from Day One: When pitching to MYSC or other deep tech investors, include a clear roadmap for utilizing the Thailand or Indonesia outposts. Highlight how you will use these hubs for rapid regulatory validation, local partnerships, or pilot testing. Demonstrating a capital-efficient global expansion strategy will significantly boost your valuation and investor appeal.